|
How much would increasing data
quality and study efficiency add to your bottom line?

|
 |
CRO/SMO
Contract Research Organizations (CROs) are under tremendous pressure as the pharmaceutical
companies increasingly rely on them to shorten drug development timelines, improve compound
quality and increase cost-effectiveness. The challenge for CROs lies in building long-term,
risk-sharing relationships with pharmaceutical companies by improving productivity, applying
ingenuity and delivering service excellence.
With explosive competition among CROs, and increased demand for speed and cost-effectiveness,
are any of the following negatively impacting your ability to reduce cycle obstacles and increase
time to market?
- Qualification of investigative sites is too labor intensive and time consuming
- Data collection and data management processes are not automated enough creating bottlenecks
and inefficiencies
- Overall number of studies do not make use of Web-enabled and voice-response technologies,
causing lost revenues and delayed study deadlines
- Delays in study start-up due to lack of automation, causing lost revenues for both you and
sponsors
- Sponsors demanding EDC studies, but your existing software technology is not suitable
- Lack of integration between your existing software technologies causing you to realize less
ROI on technology investment than you deserve
Your company's reputation is on the line each time you start a new study. SST can help you implement new technologies that can cut investigator recruitment time by as much as 75%,
speed the collection of data and
streamline communications. What would
that mean to your reputation? |